

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/2025-26/217

Date 14-11-2025

To.

Department of Corporate Services
BSE Limited
P J Tower, Dalal Street
Mumbai-400001

Ref: - BSE Security Code: 540694

Sub - Unaudited financial result (standalone and consolidated) for the quarter & half year ended 30th September, 2025.

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held on today i.e. 14th November, 2025, has inter-alia approved the Unaudited Financial Result (standalone & consolidated) for the quarter & half year ended 30th September, 2025. Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 please find enclosed as follow:


- (1) Unaudited financial result (standalone and consolidated) as per India Accounting Standards for the quarter & half year ended 30th September 2025; and
- (2) Limited review report (standalone and consolidated) by M/s Khurana Sharma & Co., Statutory Auditor of the Company.
- (3) Took note on the appointment of Cost Auditor, M/s Shreya Sahu & Associates as Cost Auditor (FRN 101389) for FY 2025-26.

The Board meeting was commenced at 05:00 pm and concluded at 06:25 pm.

Kindly take the same on your record.

Yours faithfully,

For **ANG Lifesciences India Limited**


Rajesh Gupta
Managing Director
DIN: 01423407

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Standalone Statement of Assets and Liabilities			(₹ in lacs)
Particulars	As at 30 September 2025	As at 31 March 2025	
	(Unaudited)	(Audited)	
A. Assets			
1. Non-current assets			
(a) Property, plant and equipment	4,776.45	5,017.02	
(b) Right of use assets	202.21	246.16	
(c) Financial assets			
i) Investments	352.00	352.00	
ii) Other financial assets	19.38	19.38	
(d) Deferred tax asset (net)	127.26	122.95	
(e) Other non-current assets	29.03	29.03	
Total non-current assets	5,506.33	5,786.54	
2. Current assets			
(a) Inventories	3,559.13	3,784.03	
(b) Financial assets			
i) Trade receivables	8,588.87	6,495.51	
ii) Cash and cash equivalents	6.82	7.91	
iii) Other bank balances	344.71	347.55	
v) Other financial assets	969.53	963.97	
(c) Other current assets	3,007.34	3,057.66	
Total current assets	16,476.40	14,656.63	
Assets held for sale	423.72	423.72	
Total assets	22,406.45	20,866.89	
B. Equity and liabilities			
Equity			
(a) Equity share capital	1,305.83	1,305.83	
(b) Other equity	5,220.29	5,375.07	
Total equity	6,526.12	6,680.90	
Liabilities			
1. Non-current liabilities			
(a) Financial liabilities			
i) Borrowings	327.22	1,333.53	
ii) Lease liabilities	138.27	186.95	
iii) Other financial liabilities	12.49	17.49	
(b) Provisions	124.06	110.56	
Total non-current liabilities	602.04	1,648.53	
2. Current liabilities			
(a) Financial liabilities			
i) Borrowings	7,251.52	5,446.80	
ii) Lease liabilities	95.00	90.38	
iii) Trade payables			
-Total outstanding dues of micro enterprises and small enterprises	2,167.29	3,297.63	
-Total outstanding dues of creditors other than micro enterprises and small enterprises	4,398.81	2,244.59	
iii) Other financial liabilities	420.64	744.51	
(b) Other current liabilities	920.72	688.49	
(c) Provisions	17.48	17.48	
(d) Current tax liabilities (net)	6.83	7.58	
Total current liabilities	15,278.29	12,537.46	
Total equity and liabilities	22,406.45	20,866.89	



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date

Statement of standalone unaudited results for the quarter and six months ended 30 September 2025 (₹ in lakhs except per share data)

Particulars	Quarter ended 30 September 2025 (Unaudited)	Quarter ended 30 June 2025 (Unaudited)	Quarter ended 30 September 2024 (Unaudited)	Six months ended 30 September 2025 (Unaudited)	Six months ended 30 September 2024 (Unaudited)	Year ended 31 March 2025 (Audited)
I Revenue from operations	2,597.05	2,453.18	3,215.88	5,050.23	4,833.55	8,991.01
II Other income	20.78	17.34	36.36	38.12	172.20	244.40
III Total revenue (I+II)	2,617.83	2,470.52	3,252.24	5,088.35	5,005.75	9,235.41
IV Expenses						
Cost of materials consumed	1,700.99	1,644.90	2,418.36	3,345.89	3,555.65	6,397.80
Changes in inventories of finished goods and work-in-progress	(56.85)	(25.30)	(241.95)	(82.15)	(293.43)	(338.86)
Employee benefits expense	386.35	349.43	378.79	735.78	729.28	1,445.07
Finance costs	158.73	160.62	187.24	319.35	354.18	730.37
Depreciation and amortisation expenses	145.38	144.62	161.97	290.00	313.04	627.02
Other expenses	344.91	298.92	414.62	643.83	788.69	1,667.75
Total expenses (IV)	2,679.51	2,573.19	3,319.03	5,252.70	5,447.41	10,529.15
V Loss before exceptional items and tax (III-IV)	(61.68)	(102.67)	(66.79)	(164.35)	(441.66)	(1,293.74)
VI Exceptional items						
VII Loss before tax (V-VI)	(61.68)	(102.67)	(66.79)	(164.35)	(441.66)	(1,293.74)
Tax expense						
(1) Current tax						
(2) Deferred tax	18.31	(23.94)	40.60	(5.63)	(57.74)	(259.45)
VIII Total tax expense (1+2)	18.31	(23.94)	40.60	(5.63)	(57.74)	(259.45)
IX Loss for the period (VII-VIII)	(79.98)	(78.73)	(107.39)	(158.71)	(383.92)	(1,034.29)
X Other comprehensive income:						
Items that will not be reclassified to profit or (loss)	2.63	2.63	12.44	5.26	12.44	10.52
Income tax relating to items that will not be reclassified to profit or loss	(0.66)	(0.66)	(3.13)	(1.32)	(3.13)	(2.65)
XI Total comprehensive loss (IX+X)	(78.02)	(76.76)	(98.08)	(154.78)	(374.61)	(1,026.41)
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIII Other equity						5,375.07
XIV Earnings per equity share (of ₹ 10/- each)						
- Basic and Diluted	(0.60)	(0.59)	(0.75)	(1.19)	(2.87)	(7.86)

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date

Standalone Cash Flow Statement		(₹ in lacs)	
	Six months ended 30 September 2025	Six months ended 30 September 2024	
	(Unaudited)	(Unaudited)	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Loss before tax	(164.35)	(441.66)	
Adjustment for:			
Depreciation and amortization expense	290.00	313.04	
Bad debts written off	2.00	19.81	
Provision for expected credit loss	22.78	16.20	
Liabilities no longer required, written back	-	118.28	
Finance cost	319.35	354.18	
Interest income	(29.07)	(26.73)	
Operating profit before working capital changes	440.71	353.12	
Adjustments for movement in:			
Inventories	224.90	(438.13)	
Trade receivables	(2,118.15)	282.78	
Other financial assets	(5.57)	48.06	
Other assets	50.33	(192.90)	
Other financial liabilities	(328.87)	(62.20)	
Provisions	18.77	27.45	
Trade payables	1,023.89	(496.91)	
Other liabilities	232.23	0.78	
Cash used in operations	(461.76)	(477.95)	
Income taxes paid	(0.76)	(453.38)	
Net cash flow used in operating activities	(462.52)	(931.33)	
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(5.48)	(180.30)	
Movement in fixed deposits	2.84	180.56	
Interest received	29.07	26.73	
Net cash flow generated from investing activities	26.43	26.99	
C. CASH FLOW FROM FINANCING ACTIVITIES			
Movement in short term borrowings (net)	1,804.72	1,444.06	
Movement in long term borrowings (net)	(1,006.31)	(129.87)	
Interest paid	(306.86)	(337.52)	
Payment of lease liabilities	(56.55)	(56.56)	
Net cash flow used in financing activities	435.00	920.11	
Net Increase/(decrease) in cash and cash equivalents	(1.09)	15.77	
Cash and cash equivalents at the beginning of the year	7.91	8.53	
Cash and cash equivalents at the end of the year	6.82	24.30	
Notes:			
Cash and cash equivalents include:			
Cash on hand	6.68	23.99	
Balances with banks on current accounts	0.14	0.31	
	6.82	24.30	



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited ('the Company') is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.
2. The above unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2025 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 14 November 2025. The Statutory Auditors of the Company have expressed unmodified opinion on these results.
3. The above unaudited standalone and consolidated financial results of ANG Lifesciences India Limited ('the Company' or 'the Holding Company') and its subsidiary, Mansa Print and Publishers Limited (the Holding and the subsidiary together referred to as 'the Group') have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015, as amended and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended) and other accounting principles generally accepted in India.
4. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.
5. Previous period figures have been re-grouped/reclassified wherever necessary, to conform to current period's classification.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited



Place: Amritsar

Date: 14 November 2025

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Consolidated Statement of Assets and Liabilities		
Particulars	As at	
	30 September 2025 (Unaudited)	31 March 2025 (Audited)
(₹ in lacs)		
A. Assets		
1. Non-current assets		
(a) Property, plant and equipment	5,176.27	5,473.14
(b) Right-of-use assets	202.21	246.16
(c) Financial assets		
(i) Investments	2.57	2.57
(ii) Other financial assets	21.80	21.80
d) Income tax asset (net)	16.28	15.54
(e) Deferred tax asset (net)	734.37	637.18
(f) Other non-current assets	29.02	29.03
Total non-current assets	6,182.53	6,425.42
2. Current assets		
(a) Inventories	5,060.63	5,410.91
(b) Financial assets		
(i) Trade receivables	8,710.91	6,653.89
(ii) Cash and cash equivalents	12.89	15.73
(iii) Other bank balances	345.00	347.83
iv) Other financial assets	979.19	963.97
(c) Other current assets	2,611.62	2,710.65
(d) Current tax assets	-	-
Total current assets	17,720.24	16,102.98
Asset held for sale	423.72	430.99
Total assets	24,326.49	22,959.39
B. Equity and liabilities		
Equity		
(a) Equity share capital	1,305.83	1,305.83
(b) Other equity	4,594.94	5,091.76
Total equity	5,900.77	6,397.59
Liabilities		
1. Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	1,018.44	1,886.08
(ii) Lease liabilities	138.27	186.95
(iii) Trade payables		
(iv) Other financial liabilities	12.49	17.49
(b) Deferred tax liabilities (net)		
(c) Provisions	145.67	127.64
Total non-current liabilities	1,314.86	2,218.16
2. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	7,735.70	6,157.19
(ii) Lease liabilities	95.00	90.38
(iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	2,420.55	3,984.66
- Total outstanding dues of creditors other than micro enterprises and small enterprises	5,112.99	2,622.75
(iv) Other financial liabilities	459.72	446.98
(b) Other current liabilities	1,262.59	1,013.82
(c) Provisions	17.48	20.28
(d) Current tax liabilities (net)	6.83	7.58
Total current liabilities	17,110.86	14,343.63
Total equity and liabilities	24,326.49	22,959.39



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of consolidated unaudited results for the quarter and six months ended 30 Sep 2025

(₹ in lakhs except per share data)

Particulars	Quarter ended 30 Sep 2025 (Unaudited)	Quarter ended 30 June 2025 (Unaudited)	Quarter ended 30 September 2024 (Unaudited)	Six months ended 30 September 2025 (Unaudited)	Six months ended 30 September 2024 (Unaudited)	Year ended 31 March 2025 (Audited)
I Revenue from operations	2,605.37	2,460.36	3,288.47	5,065.73	5,129.47	9,284.66
II Other income	12.25	8.90	34.87	21.15	163.35	201.18
III Total revenue (I+II)	2,617.62	2,469.26	3,323.34	5,086.88	5,292.82	9,485.84
IV Expenses						
Cost of materials consumed	1,805.12	1,642.76	2,413.04	3,447.88	3,637.31	6,390.30
Changes in inventories of finished goods and work-in-progress	(20.93)	(20.42)	(267.66)	(41.35)	(325.03)	(428.03)
Employee benefits expense	431.91	436.31	457.64	868.22	884.05	1,745.24
Finance costs	189.35	193.69	218.31	383.04	426.65	868.78
Depreciation and amortisation expenses	152.30	152.78	174.22	305.08	337.54	676.01
Other expenses	381.29	337.26	456.62	718.55	875.27	1,803.91
Total expenses (IV)	2,939.04	2,742.38	3,452.17	5,681.42	5,835.79	11,056.21
V Loss before exceptional items and tax (III-IV)	(321.41)	(273.12)	(128.83)	(594.53)	(542.97)	(1,570.37)
VI Exceptional items	-	-	-	-	-	-
VII Loss before tax (V-VI)	(321.41)	(273.12)	(128.83)	(594.53)	(542.97)	(1,570.37)
Tax expense						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(26.68)	(72.51)	80.09	(99.18)	(26.75)	(329.04)
VIII Total tax expense (1+2)	(26.68)	(72.51)	80.09	(99.18)	(26.75)	(329.04)
IX Loss for the period (VII-VIII)	(294.73)	(200.62)	(208.92)	(495.35)	(516.22)	(1,241.33)
X Other comprehensive income:						
Items that will not be reclassified to profit or loss	2.63	2.63	12.44	5.26	12.44	15.66
Income tax relating to items that will not be reclassified to profit or loss	(0.66)	(0.66)	(3.13)	(1.32)	(3.13)	(3.94)
XI Total comprehensive income (IX+X)	(292.77)	(198.65)	(199.61)	(491.41)	(506.91)	(1,229.61)
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIII Other equity						
XIV Earnings per equity share (of ₹ 10/- each)						
a) Basic	(2.24)	(1.52)	(1.53)	(3.76)	(3.88)	(9.42)
b) Diluted	(2.24)	(1.52)	(1.53)	(3.76)	(3.88)	(9.42)

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Consolidated Cash Flow Statement		(₹ in lacs)	
	Six months ended 30 September 2025	Six months ended 30 September 2024	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Loss before tax	(594.53)	(542.97)	
Adjustment for:			
Depreciation and amortization expense	305.08	337.54	
Bad debts written off	2.00	19.81	
Provision for expected credit loss	22.78	16.20	
Finance cost	383.04	426.65	
Interest income	(17.91)	(10.29)	
Loss on sale of property, plant and equipment	1.22		
Liabilities no longer required, written back	-	(118.28)	
Operating profit before working capital changes	101.68	128.66	
Adjustments for movement in:			
Inventories	350.27	(535.27)	
Trade receivables	(1,582.94)	349.51	
Other financial assets	17.06	54.05	
Other assets	66.69	(176.83)	
Other financial liabilities	(373.61)	(66.80)	
Provisions	20.49	30.17	
Trade payable	808.61	(183.79)	
Other liabilities	250.72	4.24	
Cash generated from operations	(341.02)	(396.06)	
Income taxes paid	(0.84)	(453.77)	
Net cash flow generated from operating activities	(341.87)	(849.83)	
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(5.47)	(180.30)	
Proceeds from sale of property, plant and equipment	40.00	-	
Movement in fixed deposits	2.83	180.56	
Interest received	17.91	10.29	
Net cash flow used in investing activities	55.27	10.55	
C. CASH FLOW FROM FINANCING ACTIVITIES			
Movement in long term borrowings (net)	(697.02)	(144.41)	
Movement in short term borrowings (net)	1,407.88	1,448.72	
Interest paid	(370.55)	(405.47)	
Payment of lease liabilities	(56.55)	(56.56)	
Net cash flow used in financing activities	283.76	842.28	
Net Increase/(decrease) in cash and cash equivalents	(2.84)	3.00	
Cash and cash equivalents at the beginning of the year	15.73	31.85	
Cash and cash equivalents at the end of the year	12.88	34.85	
Notes:			
Cash and cash equivalents include:			
Cash on hand	12.50	34.29	
Balances with banks on current accounts	0.39	0.56	
	12.89	34.85	



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment revenue						
	a) Pharmaceuticals	2,597.06	2,453.17	3,215.88	5,050.23	4,833.55	8,991.00
	b) Printing and packagings	113.02	34.35	202.68	147.37	504.59	676.32
	Total	2,710.09	2,487.52	3,418.56	5,197.61	5,338.15	9,667.33
	Less: Inter segment revenue	104.71	27.16	130.09	131.87	208.67	382.66
	Revenue from operations	2,605.37	2,460.36	3,288.47	5,065.73	5,129.47	9,284.66
2	Segment results (profit before tax and finance cost from each segment)						
	a) Pharmaceuticals	97.07	57.96	120.46	155.03	(87.48)	(563.38)
	b) Printing and packagings	(217.24)	(125.53)	(15.43)	(342.77)	(5.15)	(90.84)
	Total	(120.17)	(67.57)	105.03	(187.74)	(92.63)	(654.22)
	Less: Finance costs	201.23	205.56	233.86	406.79	450.34	916.15
	Loss before tax	(321.40)	(273.13)	(128.83)	(594.53)	(542.97)	(1570.36)
	Particulars				As at 30 September 2025 (Unaudited)	As at 30 September 2024 (Unaudited)	As at 31 March 2025 (Audited)
3	Segment Assets						
	a) Pharmaceuticals				22,406.47	21,787.89	20,866.90
	b) Printing and packagings				3,257.06	3,200.13	3,313.87
	Total Segment assets				25,663.53	25,008.02	24,180.77
4	Segment liabilities						
	a) Pharmaceuticals				15,278.28	14,455.17	12,537.47
	b) Printing and packagings				2,423.75	3,132.56	2,305.05
	Total Segment liabilities				17,702.03	17,587.73	14,842.52



KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and year to date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone financial results ('the Statement') of ANG Lifesciences India Limited (the Company') for the quarter and half year ended on 30 September 2025, ('the statement') attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down' in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations, Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in Scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently,

does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurana Sharma & Co.

Chartered Accountants

Firm Registration No. 010920N



CA Atul Khurana

Membership No: 568524

Date: 14-11-2025

UDIN: 25568524BMKPPY5092

KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and year to date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated financial results ('the statement') of ANG Lifesciences India Limited ('the Holding Company') and its Wholly owned Subsidiary (the Holding Company and its subsidiary together referred to as 'the Group') for the quarter ended 30 September 2025 and the consolidated year to date results for the period 1st April 2025 to 30th September 2025, being submitted by the Holding Company pursuant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the presentation Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations, Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India, A review Of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and

consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD 1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

5. The statement includes the result of the following entities:

Mansa Print & Publishers Ltd (Wholly Owned Subsidiary Company)

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurana Sharma & Co.

Chartered Accountants

Firm Registration No. 010920N



CA. Vibhor Khurana

Membership No: 568524

Date: 14-11-2025

UDIN: 25568524BMKPPX1116